Telehealth platform for treating opioid use disorders
A Pilot Study of Telehealth Treatment for Opioid Use Disorders
This study tests a telehealth program to see if it can help adults with serious opioid use issues get started on treatment after they've had an overdose.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Yale University Academic / other |
| Locations | 1 site (New Haven, Connecticut) |
| Trial ID | NCT05832879 on ClinicalTrials.gov |
What this trial studies
This study evaluates a telehealth platform designed to support adults with moderate or severe opioid use disorder who have experienced at least one overdose. The primary goal is to assess the platform's effectiveness in motivating participants to engage in medication for opioid use disorder (MOUD) treatment. Participants will be monitored for their attendance at the first MOUD appointment and subsequent overdose events over a 90-day period. The study also aims to gather data on the feasibility, acceptability, and satisfaction of both participants and healthcare providers involved in the intervention.
Who should consider this trial
Good fit: Ideal candidates are adults with moderate or severe opioid use disorder who have a history of at least one opioid overdose.
Not a fit: Patients currently using buprenorphine, methadone, or naltrexone for substance use disorder may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve access to treatment for individuals with opioid use disorder, potentially reducing overdose rates.
How similar studies have performed: Other studies have shown promising results using telehealth approaches for substance use disorders, indicating potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Can speak, read and write in English * Provision of signed and dated informed consent form * Have a history of at least one opioid overdose * Screened positive for OUD, moderate or severe, based on the Diagnostic and Statistical Manual-5th Edition * Have a working cell phone number and working device that can access a web browser and receive texts (i.e., smartphone, tablet or computer) OR be willing to use a device provided by the study team * Can provide a working email address OR be willing to create one Exclusion Criteria: * Current use of buprenorphine, methadone, or naltrexone for a substance use disorder * Pregnancy or lactation * Known current suicide risk based on participant self-report * On parole or incarcerated at time of enrollment based on participant self-report
Where this trial is running
New Haven, Connecticut
- Yale School of Medicine — New Haven, Connecticut, United States (Recruiting)
Study contacts
- Principal investigator: Rebekah Heckmann, MD, MPH, MPA — Yale University
- Study coordinator: Rebekah Heckmann, MD, MPH, MPA
- Email: rebekah.heckmann@yale.edu
- Phone: (203) 737-8335
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.